Ken Griffin Akero Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,200 shares of AKRO stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,200
Previous 57,800
28.72%
Holding current value
$1.17 Million
Previous $1.36 Million
12.77%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$224 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$201 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$168 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$158 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$148 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.32B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...